Ontology highlight
ABSTRACT: Background
The benefits of neoadjuvant therapy for patients with locally advanced gastric cancer (GC) are increasingly recognized. The 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual first proposed ypTNM staging, but its accuracy is controversial. This study aims to develop a modified ypTNM staging.Patients and methods
Clinicopathological data of 1,791 patients who underwent curative-intent gastrectomy after neoadjuvant therapy in the Surveillance, Epidemiology, and End Results database, as the development cohort, were retrospectively analyzed. Modified ypTNM staging was established based on overall survival (OS). We compared the prognostic performance of the AJCC 8th edition ypTNM staging and the modified staging for patients after neoadjuvant therapy.Results
In the development cohort, the 5-year OS for AJCC stages I, II, and III was 58.8%, 39.1%, and 21.6%, respectively, compared with 69.9%, 54.4%, 34.4%, 24.1%, and 13.6% for modified ypTNM stages IA, IB, II, IIIA, and IIIB. The modified staging had better discriminatory ability (C-index: 0.620 vs. 0.589, p < .001), predictive homogeneity (likelihood ratio chi-square: 140.71 vs. 218.66, p < .001), predictive accuracy (mean difference in Bayesian information criterion: 64.94; net reclassification index: 35.54%; integrated discrimination improvement index: 0.032; all p < .001), and model stability (time-dependent receiver operating characteristics curves) over AJCC. Decision curve analysis showed that the modified staging achieved a better net benefit than AJCC. In external validation (n =?266), the modified ypTNM staging had superior prognostic predictive power (all p < .05).Conclusion
We have developed and validated a modified ypTNM staging through multicenter data that is superior to the AJCC 8th edition ypTNM staging, allowing more accurate assessment of the prognosis of patients with GC after neoadjuvant therapy.Implications for practice
The 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual first proposed ypTNM staging, but its accuracy is controversial. Based on multi-institutional data, this study developed a modified ypTNM staging, which is superior to the AJCC 8th edition ypTNM staging, allowing more accurate assessment of the prognosis of patients with gastric cancer after neoadjuvant therapy.
SUBMITTER: Zhong Q
PROVIDER: S-EPMC7794192 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Zhong Qing Q Chen Qi-Yue QY Parisi Amilcare A Ma Yu-Bin YB Lin Guang-Tan GT Desiderio Jacopo J Yan Su S Xie Jian-Wei JW Wang Jia-Bin JB Hou Jun-Fang JF Lin Jian-Xian JX Lu Jun J Cao Long-Long LL Lin Mi M Tu Ru-Hong RH Huang Ze-Ning ZN Lin Ju-Li JL Liu Zhi-Yu ZY Que Si-Jin SJ Li Ping P Zheng Chao-Hui CH Huang Chang-Ming CM
The oncologist 20200917 1
<h4>Background</h4>The benefits of neoadjuvant therapy for patients with locally advanced gastric cancer (GC) are increasingly recognized. The 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual first proposed ypTNM staging, but its accuracy is controversial. This study aims to develop a modified ypTNM staging.<h4>Patients and methods</h4>Clinicopathological data of 1,791 patients who underwent curative-intent gastrectomy after neoadjuvant therapy in the Surveillance, Epi ...[more]